Cladribine for treating relapsing–remitting multiple sclerosis

The UK multiple sclerosis (MS) population is expected to increase annually by 2.4%1. Cladribine offers an orally administered option for highly active relapsing-remitting MS, avoiding the need for infusions, and requires less frequent dosing and monitoring compared to other therapies.

Project overview

The HIN will support the MS networks covering southeast and southwest London, led by King’s College Hospital NHS Foundation Trust and St George’s University Hospitals NHS Foundation Trust respectively, in optimising patient access to appropriate disease modifying therapy options, including Cladribine. Where in the past patients may have needed to travel for diagnostics and treatment, including possibly lengthy waiting times for infusion treatments, the project aims to give more patients the option for treatment closer to home with the most appropriate disease modifying therapies. This includes the option of Cladribine.

In addition to work with local partners, the HIN will share learnings from south London with the wider AHSN Network team, to further inform delivery in areas with lower prescribing rates.

Please click here to see the MS treatment pathway.

Since prescribing of Cladribine has restarted post-Covid 19 wave 1, in line with ABN guidance, the project will focus on supporting the south London teams in reintroducing Cladribine as a treatment option for patients with relapsing-remitting MS.

1MacKenzie et al. J Neurol Neurosurg Psychiatry. 2014 Jan;85(1):76-84.

We're here to help

To find out more, contact the innovation technology product team.

Email us
 

By Rita Mogaiji

Share: